Last Updated: June 22, 2026

NEOSTIGMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Neostigmine patents expire, and what generic alternatives are available?

Neostigmine is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Amring Pharms, Avet Lifesciences, Be Pharms, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Meitheal, Nivagen Pharms Inc, Ph Health, Regcon Holdings, and Sagent Pharms Inc. and is included in nineteen NDAs.

The generic ingredient in NEOSTIGMINE is neostigmine methylsulfate. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Neostigmine

A generic version of NEOSTIGMINE was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8th, 2015.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for NEOSTIGMINE?
  • What are the global sales for NEOSTIGMINE?
  • What is Average Wholesale Price for NEOSTIGMINE?
Summary for NEOSTIGMINE
US Patents:0
Applicants:17
NDAs:19
Drug Prices: Drug price information for NEOSTIGMINE
DailyMed Link:NEOSTIGMINE at DailyMed
Drug patent expirations by year for NEOSTIGMINE
Drug Prices for NEOSTIGMINE

See drug prices for NEOSTIGMINE

US Patents and Regulatory Information for NEOSTIGMINE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ph Health NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 208405-001 Apr 26, 2017 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Meitheal NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 212804-001 Apr 5, 2021 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ph Health NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 208405-002 Apr 26, 2017 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Meitheal NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 212804-002 Apr 5, 2021 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Am Regent NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 209182-001 May 4, 2018 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Eugia Pharma NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 213244-001 Nov 2, 2023 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for NEOSTIGMINE
Neostigmine class of drug?
Neostigmine methylsulfate price?
Neostigmine methylsulfate glycopyrrolate reviews?
Neostigmine methylsulfate injection market?
Neostigmine methylsulfate cost?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links